Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
MRK News
recently showcased significant advancements by unveiling positive results from its Phase 3 STRIDE-13 Trial of the CAPVAXIVE vaccine, signaling progress in vacci...
Healthcare Merck says trial data for pneumonia shot Capvaxive shows promise in younger people Sep. 11, 2025 7:18 AM ET Merck & Co., Inc. (MRK) Stock By: Dulan L...
Merck (MRK) announced positive results from the Phase 3 STRIDE-13 trial evaluating capvaxive – Pneumococcal 21-valent Conjugate Vaccine – at the 6th European So...
Analyst ratings
59%
of 27 ratingsMore MRK News
Merck (NYSE:MRK) has canceled plans for a £1B research center in London and will lay off over 100 scientists, the Financial Times reported on Wednesday. This d...
Merck (MRK) plans to lay off more than 100 scientific staff as it scraps its GBP 1B research center in London, The Financial Times’ Hannah Kuchler and Patrick T...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Summit Therapeutics Inc. SMMT, on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 Wo...
In the past week, Merck and Daiichi Sankyo reported that ifinatamab deruxtecan showed clinically meaningful response rates in previously treated extensive-stage...
Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan demonstrated clinically meaningful response rates in patients with previously tre...